Price Crosses Moving Average
Previous Close | 5.81 |
Open | 5.98 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's Range | 5.79 - 6.07 |
52 Week Range | 3.65 - 27.22 |
Volume | |
Avg. Volume | 378,849 |
Market Cap | 154.302M |
Beta (5Y Monthly) | 2.49 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -13.59 |
Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.08 |
Inotiv, Inc. (NOTV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
WEST LAFAYETTE, Ind., May 25, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will present at the Jefferies Healthcare Conference, being held in New Yor
WEST LAFAYETTE, Ind., May 19, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today its participation in the following investor conferences: Benchmark Healthcare House Call Conference (Virtual)One-on-one meetings: May 23, 2023 Craig-Hallum Institutional Investor C
The average of price targets set by Wall Street analysts indicates a potential upside of 169% in Inotiv, Inc. (NOTV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Inotiv ( NASDAQ:NOTV ) Second Quarter 2023 Results Key Financial Results Revenue: US$151.5m (up 7.9% from 2Q 2022). Net...
Inotiv, Inc. (NOTV) delivered earnings and revenue surprises of -112.50% and 13.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Updates Select Full Year Fiscal 2023 Financial GuidanceWEST LAFAYETTE, Ind., May 11, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2023”) and six months (“YTD FY 2023”) ended March 31, 2023. Financial Highligh
While Inotiv, Inc. ( NASDAQ:NOTV ) shareholders are probably generally happy, the stock hasn't had particularly good...
4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
WEST LAFAYETTE, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, and research models and related products and services, announced today the expansion of the Company’s safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in cynomolgus macaques. Offered through Inotiv’s Discovery and Safety Assessment
WEST LAFAYETTE, Ind., April 26, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, on Thursday, May 11, 2023, after the close of the stock market. The Company will
Recently, Frost & Sullivan assessed the bio-analytical testing services industry and, based on its findings, recognized Inotiv, Inc. (Nasdaq: NOTV) with the 2022 North American Customer Value Leadership Award. Inotiv addresses the needs of bio-analytical, non-clinical, and clinical research drug and device developers by operating in contract research services and research product business segments. It offers a range of experienced scientists and state of the art facilities to provide highly comp
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Investors need to pay close attention to Inotiv (NOTV) stock based on the movements in the options market lately.
Wasatch Global Investors, an asset management company, released its “Wasatch Micro Cap Growth—U.S. Strategy” fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy declined and underperformed its benchmark, the Russell Microcap Index in the fourth quarter, which gained 4.72%. The disappointing returns in industrials, financials, and consumer discretionary were the […]
Key Insights The considerable ownership by individual investors in Inotiv indicates that they collectively have a...
Inotiv, Inc. (NASDAQ:NOTV) Q1 2023 Earnings Call Transcript February 13, 2023 Operator: Hello, and welcome to Inotiv Inc.’s First Quarter Fiscal 2023 Financial Results Conference Call and Webcast. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It’s now my pleasure to turn the call over to Devin […]
Reiterates Select Full Year Fiscal 2023 Financial GuidanceWEST LAFAYETTE, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2023”) ended December 31, 2022. Financial Highlights Q1 FY 2023 Highlights
WEST LAFAYETTE, Ind., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022 on Monday, February 13, 2023 after the close of the stock market. The Company wi
WEST LAFAYETTE, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that it has earned the 2023 Top Workplaces USA award, issued by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplac
WEST LAFAYETTE, Ind., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that David Landman has been designated by Jermyn Street Associates LLC as its Shareholder Representative on the Board of Directors, replacing Scott Cragg, who is stepping down to
Inotiv, Inc. (NASDAQ:NOTV) Q4 2022 Earnings Call Transcript January 10, 2023 Inotiv, Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were $-0.37. Operator: Greetings, and welcome to the Inotiv, Inc.’s Fourth Quarter and Full Year Fiscal 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer […]
Provides Select First Quarter and Full Year Fiscal 2023 Financial GuidanceWEST LAFAYETTE, Ind., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q4 FY 2022”) and twelve months (“FY 2022”) ended September 30, 2
WEST LAFAYETTE, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 fourth quarter and full year ended September 30, 2022 on Tuesday, January 10, 2023 after the cl
In this article, we discuss the 10 stocks under $20 to buy now. If you want to read about some more high potential stocks, go directly to 5 Stocks Under $20 to Buy Now. In an era of soaring market valuations, cheap stocks offer investors from across the spectrum a healthy chance to make handsome […]